Beauty Health (SKIN) Insider Grant Boosts Stake to 243,035 Shares

Rhea-AI Filing Summary

Beauty Health Company (ticker: SKIN) filed a Form 4 disclosing an insider equity grant. Director Brian Christopher Miller received 73,051 Class A common-stock RSUs on 16 June 2025. The award is classified as an acquisition (Code A) and is part of routine director compensation.

The RSUs will vest on the earlier of the one-year anniversary of the grant or the 2026 annual shareholder meeting, subject to Miller’s continued board service. Following the grant, Miller’s beneficial ownership increased to 243,035 shares, held directly. No derivative securities or sales were reported, and no 10b5-1 trading plan was indicated.

Insights

Corporate Governance Analyst

TL;DR: Routine RSU grant; neutral governance impact, no buying or selling pressure expected.

The filing reflects standard board remuneration rather than an opportunistic purchase or divestiture. While the 73,051-share award is sizeable in absolute terms, it represents normal annual equity compensation and does not signal a shift in insider sentiment. Vesting aligns with typical best-practice timelines, linking director retention to shareholder meeting cadence. Because the disclosure involves no cash outlay, leverage, or sale, immediate market impact should be negligible. Investors may view steady insider equity accumulation as modestly positive for alignment, but material valuation effects are unlikely.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Brian Christopher

(Last) (First) (Middle)

C/O THE BEAUTY HEALTH COMPANY

2165 SPRING STREET

(Street)

LONG BEACH CA 90806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beauty Health Co [ SKIN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A(1)		73,051	A(1)	(1)	243,035	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). The RSUs vest on the earlier of the one-year anniversary of the grant and the date of the 2026 Annual Meeting of Stockholders of the Company, contingent upon the reporting person's continued service as a member of the Company's board of directors through such time.

Remarks:

	/s/ Brian Christopher Miller	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the SKIN Form 4 reveal about insider activity?

Director Brian C. Miller was granted 73,051 RSUs on 16 Jun 2025; no shares were sold.

How many SKIN shares does Brian Miller now own?

After the grant, Miller beneficially owns 243,035 Class A common shares.

When do the newly granted RSUs vest?

They vest on the earlier of one year from grant or the 2026 Annual Meeting, contingent on continued board service.

Was a Rule 10b5-1 trading plan disclosed in this Form 4?

No. The filing does not indicate that the transaction was executed under a Rule 10b5-1 plan.

Does this filing signal a change in insider sentiment?

The grant is routine compensation; it does not necessarily reflect a directional view on SKIN’s valuation.